<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02575378</url>
  </required_header>
  <id_info>
    <org_study_id>ZHYY-ZYYZX-rjzl</org_study_id>
    <nct_id>NCT02575378</nct_id>
  </id_info>
  <brief_title>Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimum regimen of maintenance treatment after first-line chemotherapy in patients with
      metastatic colorectal cancer （mCRC） is unknown. This study was designed to determine the
      efficacy and safety of maintenance treatment with capecitabine metronomic chemotherapy plus
      Chinese Traditional Medicine.

      In this Prospective, open-label, randomised controlled trial, the investigators will recruit
      159 mCRC patients who have finished 18 to 24 weeks first-line chemotherapy and disease
      evaluation is SD, PR or CR. The patients will then accept Chinese traditional diagnosis and
      be randomised into two group, capecitabine metronomic chemotherapy only as control group and
      the metronomic chemotherapy plus Chinese Traditional Medicine as experimental group. This
      treatment regimen will be continued until progression, death, or an unacceptable adverse
      event.

      The primary endpoint is progression-free survival (PFS). Secondary endpoints are overall
      survival (OS), quality of life (QOL) and toxic effects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>six months</time_frame>
    <description>from randomising to progression, death, unacceptable AE</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Metronomic chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronimic chemotherapy plus Chinese Traditional Medicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.
Chinese Traditional Medicine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronimic chemotherapy plus Chinese Traditional Medicine</intervention_name>
    <description>Capecitabine 300mg/m2, twice a day, everyday plus Chinese Traditional Medicine</description>
    <arm_group_label>Metronimic chemotherapy plus Chinese Traditional Medicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronimic chemotherapy</intervention_name>
    <description>Capecitabine 300mg/m2, twice a day, everyday</description>
    <arm_group_label>Metronomic chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. unresectable metastatic colorectal cancer with pathological confirmation.

          2. patients have accepted 18-24 weeks first-line chemotherapy and disease evaluation is
             SD, PR or CR.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>October 13, 2015</last_update_submitted>
  <last_update_submitted_qc>October 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Hao Li</investigator_full_name>
    <investigator_title>associate chief physician, Department of Oncology</investigator_title>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>Maintenance Treatment</keyword>
  <keyword>Chinese Traditional Medicine</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

